HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.

Abstract
AT-101 is a BH3 mimetic and pan-Bcl-2 inhibitor that has shown potent anticancer activity in non-small-cell lung cancer (NSCLC) in murine models, but failed to show clinical efficacy when used in combination with docetaxel in NSCLC patients. Our recent study has demonstrated that AT-101 enhanced the antitumor effect of cisplatin (CDDP) in a murine model of NSCLC via inhibition of the interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway. This study explored the underlying mechanisms for the enhanced anticancer activity of CDDP by AT-101. Our results show that, when compared with monotherapy, AT-101 significantly enhanced the inhibitory effects of CDDP on proliferation and migration of A549 cells and on tube formation and migration in human umbilical vein endothelial cells. AT-101 promoted the proapoptotic activity of CDDP in A549 cells. AT-101 also enhanced the inhibitory effect of CDDP on DNA repair and redox activities of apurinic/apyrimidinic endonuclease 1 (APE1) in A549 cells. In tumor tissues from nude mice treated with AT-101 plus CDDP or monotherapy, the combination therapy resulted in greater inhibition of angiogenesis and tumor cell proliferation than the monotherapy. These results suggest that AT-101 can enhance the antitumor activity of CDDP in NSCLC via inhibition of APE1 DNA repair and redox activities and by angiogenesis and induction of apoptosis, but other mechanisms cannot be excluded. We are now conducting a Phase II trial to examine the clinical efficacy and safety profile of combined use of AT-101 plus CDDP in advanced NSCLC patients.
AuthorsTao Ren, Jinlu Shan, Mengxia Li, Yi Qing, Chengyuan Qian, Guangjie Wang, Qing Li, Guoshou Lu, Chongyi Li, Yu Peng, Hao Luo, Shiheng Zhang, Yuxing Yang, Yi Cheng, Dong Wang, Shu-Feng Zhou
JournalDrug design, development and therapy (Drug Des Devel Ther) Vol. 9 Pg. 2887-910 ( 2015) ISSN: 1177-8881 [Electronic] New Zealand
PMID26089640 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • APEX1 protein, human
  • DNA-(Apurinic or Apyrimidinic Site) Lyase
  • Gossypol
  • Cisplatin
  • gossypol acetic acid
Topics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, pharmacology)
  • Apoptosis (drug effects)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cisplatin (administration & dosage, pharmacology)
  • DNA Repair (drug effects)
  • DNA-(Apurinic or Apyrimidinic Site) Lyase (metabolism)
  • Gossypol (administration & dosage, analogs & derivatives, pharmacology)
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Lung Neoplasms (drug therapy, pathology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neovascularization, Pathologic (drug therapy)
  • Oxidation-Reduction (drug effects)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: